{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:32:19Z","timestamp":1783006339919,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.clinthera.2007.10.009","type":"journal-article","created":{"date-parts":[[2007,11,26]],"date-time":"2007-11-26T21:27:33Z","timestamp":1196112453000},"page":"2134-2153","source":"Crossref","is-referenced-by-count":69,"title":["Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"29","author":[{"given":"Neal","family":"Benedict","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Seybert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mathier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.10.009_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"issue":"Suppl 12","key":"10.1016\/j.clinthera.2007.10.009_bib3","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension","volume":"43","author":"Simonneau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200108023450502","article-title":"Mutation in the gene for bone morphogenic protein receptor II as a cause of primary pulmonary hypertension in a large kindred","volume":"345","author":"Newman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib5","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1161\/01.CIR.0000132476.87231.6F","article-title":"Pulmonary arterial hypertension: Future directions: Report of a National Heart, Lung and Blood Institute\/Office of Rare Diseases workshop","volume":"109","author":"Newman","year":"2004","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.10.009_bib6","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1378\/chest.126.1_suppl.14S","article-title":"Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"McGoon","year":"2004","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.10.009_bib7","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","article-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2007.10.009_bib8","series-title":"Executive Summary from the World Symposium on Primary Pulmonary Hypertension","year":"1998"},{"key":"10.1016\/j.clinthera.2007.10.009_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","article-title":"Psychophysical bases of perceived exertion","volume":"14","author":"Borg","year":"1982","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.clinthera.2007.10.009_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.7326\/0003-4819-143-4-200508160-00009","article-title":"Evaluation and management of the patient with pulmonary arterial hypertension","volume":"143","author":"Rubin","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib12","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2007.10.009_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib15","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib16","series-title":"Flolan (epoprostenol) [package insert]","year":"2002"},{"key":"10.1016\/j.clinthera.2007.10.009_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1378\/chest.124.6.2087","article-title":"Treatment of pulmonary arterial hypertension: A preliminary decision analysis","volume":"124","author":"Highland","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2007.10.009_bib21","series-title":"Remodulin (treprostinil) [package insert]","year":"2006"},{"key":"10.1016\/j.clinthera.2007.10.009_bib22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A doubleblind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharm"},{"key":"10.1016\/j.clinthera.2007.10.009_bib24","series-title":"Ventavis (iloprost) [package insert]","year":"2006"},{"key":"10.1016\/j.clinthera.2007.10.009_bib25","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib27","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0195-668X(02)00302-0","article-title":"Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation","volume":"24","author":"Opitz","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib29","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib30","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2007.10.009_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib33","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin- A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib34","series-title":"Ambrisentan (Letairis) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2007.10.009_bib35","series-title":"Tracleer (bosentan) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2007.10.009_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.10.009_bib37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib38","series-title":"Revatio (sildenafil) [manufacturer information]","year":"2005"},{"key":"10.1016\/j.clinthera.2007.10.009_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2007.10.009_bib40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib41","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 12S","key":"10.1016\/j.clinthera.2007.10.009_bib42","doi-asserted-by":"crossref","first-page":"48S","DOI":"10.1016\/j.jacc.2004.02.010","article-title":"End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives","volume":"43","author":"Hoeper","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib43","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib44","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","article-title":"Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension","volume":"108","author":"Michelakis","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2007.10.009_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","article-title":"Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids","volume":"22","author":"Hoeper","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib48","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.123.4.1293","article-title":"Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension","volume":"123","author":"Stiebellehner","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2007.10.009_bib49","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib50","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib51","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib52","first-page":"404","article-title":"Chronic oral sildenafil therapy in severe pulmonary artery hypertension","volume":"54","author":"Kothari","year":"2002","journal-title":"Indian Heart J"},{"key":"10.1016\/j.clinthera.2007.10.009_bib53","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/78.10.1207","article-title":"Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy","volume":"78","author":"Bhatia","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2007.10.009_bib54","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","article-title":"Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol","volume":"167","author":"Kuhn","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2007.10.009_bib55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2007.10.009_bib56","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: The impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2007.10.009_bib57","unstructured":"Frost AE. An update on improving survivability in pulmonary hypertension. http:\/\/www.medscape.com\/viewarticle\/508767. Accessed October 15, 2007."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807003335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807003335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T19:56:21Z","timestamp":1546458981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807003335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0149291807003335"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.10.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}